FDA Approves Forzinity for Barth Syndrome Following Congressional Advocacy
Key Insights
The FDA has granted accelerated approval to Stealth Biotherapeutics (search)' Forzinity (search) (elamipretide) for the treatment of Barth syndrome (search), a rare genetic condition affecting approximately 150 individuals in the United States.
U.S. Representative Buddy Carter played a key advocacy role in securing the approval, including writing letters to the FDA and highlighting patient testimonials about the drug's life-changing impact.
The approval represents a significant milestone for patients with Barth syndrome (search), with Carter stating that "lives will be saved because of the FDA's decision today."
The FDA has granted accelerated approval to Forzinity (search) (elamipretide), developed by Stealth Biotherapeutics (search), marking a significant breakthrough for patients with Barth syndrome (search), a rare genetic condition affecting approximately 150 individuals nationwide. The approval follows sustained advocacy efforts by U.S. Representative Buddy Carter, who championed the treatment's expedited review process.
Congressional Advocacy Drives Approval Process
Representative Carter played a pivotal role in securing FDA approval for the Barth syndrome (search) treatment, including writing advocacy letters to the agency and highlighting the urgent medical need. The FDA initially accepted the resubmitted New Drug Application for elamipretide with a target decision date of September 26, 2025, but ultimately granted approval ahead of schedule.
"Lives will be saved because of the FDA's decision today," Carter stated, emphasizing the life-saving potential of this approval for families affected by the rare disease.
Patient Impact and Clinical Significance
The approval addresses a critical unmet medical need for Barth syndrome (search) patients, with compelling patient testimonials supporting the drug's therapeutic value. Carter shared feedback from a patient in Atlanta who reported that elamipretide "has allowed him to live a life he could only have dreamed of before," illustrating the treatment's transformative impact on quality of life.
Barth syndrome (search) affects approximately 150 individuals across the United States, including six patients in Georgia. The condition represents a significant burden for affected families, making the availability of an approved treatment particularly meaningful for this patient population.
Stakeholder Response
Patient advocate Haley Bower expressed gratitude for Carter's advocacy efforts and the support provided to patients throughout the approval process. The collaborative approach between congressional representatives, patient advocates, and regulatory authorities demonstrates the importance of coordinated efforts in advancing treatments for rare diseases.
The FDA's decision to grant accelerated approval reflects the agency's recognition of the significant medical need and the treatment's potential to address this rare condition where limited therapeutic options previously existed.